Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22362286 | 0.94 | SCN9A (0.50) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL23920500 | 0.93 | CHRM1 (0.54) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL22373838 | 0.86 | SCN9A (0.48) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL21050218 | 0.85 | SCN9A (0.56) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL22362258 | 0.84 | SCN9A (0.42) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL29447008 | 0.79 | CHRM1 (0.49) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL22777600 | 0.79 | CHRM1 (0.49) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL21819270 | 0.78 | ATF4 (0.50) | SCN9ACNR2 | |
| SCHEMBL15482283 | 0.77 | HTT (0.60) | CHRM1 | |
| SCHEMBL21390326 | 0.76 | SCN9A (0.55) | SCN9ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983378-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206829-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2020252205-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | CHRM1 4819/4885CHRM3 4571/4885CHRM2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.